ATE164079T1 - Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten - Google Patents

Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten

Info

Publication number
ATE164079T1
ATE164079T1 AT95907302T AT95907302T ATE164079T1 AT E164079 T1 ATE164079 T1 AT E164079T1 AT 95907302 T AT95907302 T AT 95907302T AT 95907302 T AT95907302 T AT 95907302T AT E164079 T1 ATE164079 T1 AT E164079T1
Authority
AT
Austria
Prior art keywords
parasitic infections
treating parasitic
ige antagonists
ige
antagonists
Prior art date
Application number
AT95907302T
Other languages
English (en)
Inventor
Payman Amiri
Mary Haak-Frendscho
Paula M Jardieu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE164079T1 publication Critical patent/ATE164079T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95907302T 1994-01-18 1995-01-05 Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten ATE164079T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18408394A 1994-01-18 1994-01-18

Publications (1)

Publication Number Publication Date
ATE164079T1 true ATE164079T1 (de) 1998-04-15

Family

ID=22675480

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95907302T ATE164079T1 (de) 1994-01-18 1995-01-05 Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten

Country Status (10)

Country Link
US (1) US5656273A (de)
EP (1) EP0739214B1 (de)
JP (1) JP3825798B2 (de)
AP (1) AP660A (de)
AT (1) ATE164079T1 (de)
DE (1) DE69501817T2 (de)
DK (1) DK0739214T3 (de)
MX (1) MX9602818A (de)
PH (1) PH31447A (de)
WO (1) WO1995019181A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL137649A (en) * 1998-02-18 2004-08-31 Genentech Inc Method of adsorption chromatography
WO2000015260A1 (en) * 1998-09-16 2000-03-23 Tanox, Inc. Anti-ige gene therapy
JP2003524602A (ja) * 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション IgE関連疾患の治療方法と、その治療において使用する組成物
WO2002092125A1 (en) * 2001-05-11 2002-11-21 Novartis Ag Compositions for use in treating ige-associated disorders
WO2002094228A1 (en) * 2001-05-23 2002-11-28 David Follansbee Prevention and treatment of allergies by helminthic regulation of ige
EP1472275B1 (de) 2002-02-05 2008-12-17 Genentech, Inc. Proteinaufreinigung
SI1501369T1 (sl) 2002-04-26 2015-10-30 Genentech, Inc. Neafinitetno čiščenje proteinov
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
JP4599355B2 (ja) 2003-07-28 2010-12-15 ジェネンテック, インコーポレイテッド プロテインaアフィニティークロマトグラフィーの間のプロテインaの浸出の低減
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
WO2005105106A2 (en) * 2004-04-21 2005-11-10 Roby Russell R Hormone treatment of macular degeneration
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US20110104159A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
US20110105559A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy
PT2061444E (pt) * 2006-09-11 2011-07-08 Bausch & Lomb Composições e métodos de tratamento, controlo, redução, melhoramento ou prevenção de alergias
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
RU2474585C2 (ru) 2007-01-22 2013-02-10 Дженентек, Инк. Осаждение и очистка белков полиэлектролитами
EP2586788B1 (de) 2007-07-09 2017-11-29 Genentech, Inc. Verhindern der Disulfid-Bindungsreduktion während der rekombinanten Herstellung von Polypeptiden
HUE024877T2 (en) 2007-10-30 2016-02-29 Genentech Inc Antibody purification by cation exchange chromatography
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
HUE066562T2 (hu) 2008-08-14 2024-08-28 Genentech Inc Eljárások szennyezés eltávolítására indigén fehérje kiszorításos ioncserés membrán kromatográfia alkalmazásával
EP2684570A1 (de) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Zusammensetzungen und Verfahren zur Prävention des oxidativen Abbaus von Proteinen
DK2370561T3 (da) 2008-12-16 2019-10-21 Emd Millipore Corp Omrøringstankreaktor og fremgangsmåde
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
US8435488B2 (en) 2009-02-27 2013-05-07 Genentech, Inc. Methods and compositions for protein labelling
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
BR112012004697B8 (pt) 2009-09-01 2021-05-25 Genentech Inc método para purificar um polipeptídeo compreendendo uma região ch2/ch3
KR101878369B1 (ko) 2010-03-22 2018-07-16 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
CN102892791B (zh) 2010-05-17 2017-05-17 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
JP6050226B2 (ja) 2010-05-28 2016-12-21 ジェネンテック, インコーポレイテッド Ldh及びpdhk発現を下方制御することによる乳酸レベルの低下及びポリペプチド生産の増加
KR101924653B1 (ko) 2010-06-24 2018-12-03 제넨테크, 인크. 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2013009491A2 (en) 2011-07-08 2013-01-17 Nripen Singh Improved depth filters for disposable biotechnological processes
PL2794635T3 (pl) 2011-12-22 2019-02-28 F.Hoffmann-La Roche Ag Membranowa chromatografia jonowymienna
SG11201406112TA (en) 2012-03-27 2014-10-30 Genentech Inc Improved harvest operations for recombinant proteins
SI2849723T1 (sl) 2012-05-18 2018-09-28 Genentech, Inc. Formulacije z visoko koncentracijo monoklonskih protiteles
WO2014100095A1 (en) 2012-12-19 2014-06-26 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
CN106686977B (zh) 2014-07-09 2022-03-25 豪夫迈·罗氏有限公司 Ph调整以改善细胞库的解冻复苏
JP2019510517A (ja) 2016-03-29 2019-04-18 ジェルター, インコーポレイテッド 細胞質内体積に対するペリプラズム体積の比率が0.5:1および10:1の間にあるグラム陰性細菌におけるタンパク質の発現
AU2017382281B2 (en) 2016-12-22 2024-07-11 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
IL279782B2 (en) 2018-07-03 2026-05-01 Bristol Myers Squibb Co Methods for producing recombinant proteins
KR20210074341A (ko) 2018-10-10 2021-06-21 베링거 인겔하임 인터내셔날 게엠베하 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
GB2597416A (en) 2019-04-12 2022-01-26 Geltor Inc Recombinant elastin and production thereof
US20220315887A1 (en) 2019-08-01 2022-10-06 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
CN116194570A (zh) 2020-09-22 2023-05-30 百时美施贵宝公司 用于产生治疗性蛋白的方法
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946788A (en) * 1985-06-11 1990-08-07 Ciba-Geigy Corporation Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications
US4714759A (en) * 1985-12-02 1987-12-22 Whitaker Jr Robert B Immunotoxin therapy of allergy
US4940782A (en) * 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
US4962035A (en) * 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
US5252467A (en) * 1987-12-31 1993-10-12 Tanox Biosystems, Inc. Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE
US5091313A (en) * 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
EP0617127A1 (de) * 1987-12-31 1994-09-28 Tanox Biosystems, Inc. Antigene Epitope auf B-Zell-gebundene IgE Immunglobulinen
JP2988635B2 (ja) * 1990-09-18 1999-12-13 塩野義製薬株式会社 ヒトIgEに対するモノクローナル抗体
EP1260521B1 (de) * 1991-08-14 2007-11-21 Genentech Inc. Immunglobulinvarianten für spezifische Fc-epsilon Rezeptoren
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner

Also Published As

Publication number Publication date
JP3825798B2 (ja) 2006-09-27
MX9602818A (es) 1997-06-28
PH31447A (en) 1998-11-03
AP660A (en) 1998-08-18
DE69501817D1 (de) 1998-04-23
AP9600875A0 (en) 1997-01-31
US5656273A (en) 1997-08-12
WO1995019181A1 (en) 1995-07-20
EP0739214A1 (de) 1996-10-30
JPH10503749A (ja) 1998-04-07
DE69501817T2 (de) 1998-09-10
DK0739214T3 (da) 1998-10-07
EP0739214B1 (de) 1998-03-18

Similar Documents

Publication Publication Date Title
DE69501817D1 (de) Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
DE69620848D1 (de) Photolack-Entfernungslösung und Verfahren zur Entfernung von Photolack unter Verwendung derselben
DE69624116D1 (de) Verfahren zur behandlung von allergischem asthma
DE69331469D1 (de) Verfahren zur behandlung von abfällen
DE69701714D1 (de) Verfahren zur behandlung von glassubstraten
DE69535022D1 (de) Verfahren zur verbesserung von destillat
DE69507500D1 (de) Verfahren zur behandlung von kunststoffgiessformen
DE69603255D1 (de) Verfahren zur modifizierung von oberflächen
DE69603838D1 (de) Verfahren zur behandlung von gasen
EP0820467A4 (de) Verfahren zur behandlung von augenkrankheiten
ATA124894A (de) Verfahren zur direktreduktion von eisenoxidhältigem material
DE59305971D1 (de) Verfahren zur entölung von rohlecithin
DE59810532D1 (de) Verfahren zur behandlung von cellulosischen formkörpern
ATE214388T1 (de) Verfahren zur kristallisation von losartan
DE69526796D1 (de) Verfahren zur inhibierung von pflanzenkrankheiten
DE69839723D1 (de) Verfahren und Vorrichtung zur Herstellung von Halbleiterkristallen
DE69824283D1 (de) Verfahren zur reinigung von caprolactam
EP1200538A4 (de) Verfahren zur behandlung von petroleumsäuren
DE59807142D1 (de) Verfahren zur reinigung von anlagenteilen
ATE371453T1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
DE69738323D1 (de) Verfahren zur verringerung der abbaubarkeit von futterprotein
DE69514535D1 (de) Verfahren zur raffinierung von methylal
DE69513474D1 (de) Verfahren zur Auswertung von Siliziumscheiben
DE69609082D1 (de) Verfahren zur behandlung von abfällen
DE59507436D1 (de) Verfahren zur direktreduktion von eisenoxidhältigem material

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee